Paroxetine Safety and Efficacy in Rheumatoid Arthritis - Trial NCT06231745
Access comprehensive clinical trial information for NCT06231745 through Pure Global AI's free database. This Phase 3 trial is sponsored by Mostafa Bahaa and is currently Recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Mostafa Bahaa
Tanta University
Timeline & Enrollment
Phase 3
Jan 31, 2024
Feb 20, 2026
Primary Outcome
The primary efficacy end point will be the change in the 28-joints disease activity score (DAS28).
Summary
Rheumatoid arthritis (RA) is a systemic chronic auto-inflammatory disorder which imposes a
 remarkable burden of morbidity and mortality on global health. The complex interaction
 between genetics, environment, and immunological response contribute to RA pathogenesis.
 Current treatment comprises conventional disease-modifying anti-rheumatic drugs (DMARDs)
 followed by biological DMARDs, if necessary, to achieve low disease activity or remission.
 Therapeutics used in RA had limitations in tolerability, access, and response duration and
 magnitude. Consequently, implementation of safe adjunctive treatment for RA is urgently
 needed to boost the therapeutic response.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06231745
Non-Device Trial